Tumor-derived GDF-15 to suppress T-lymphocyte recruitment to the tumor microenvironment resulting in resistance to ANTI-PD-1 treatment.
Joerg Wischhusen, Markus Haake, Neha Vashist, Sabrina Genßler, Kilian Wistuba-Hamprecht, Patrick Harter,...
Read MoreColchicine acts selectively in the liver to induce hepatokines that inhibit myeloid cell activation
Jui-Hsia Weng, Peter David Koch, Harding H. Luan, Ho-Chou Tu, Kenichi Shimada,...
Read MoreGDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma
Zhaowei Wang, Lei He, Weina Li, Chuanyang Xu, Jieyu Zhang, Desheng Wang,...
Read MoreTumor-derived GDF-15 suppresses T-lymphocyte recruitment to the tumor microenvironment
Markus Haake, Neha Vashist, Sabrina Genssler, Kristin H. Eichler, Birgitt Fischer, Jessica...
Read MoreCatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting
CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody...
Read MoreCatalYm Presents at Bioequity Europe May 17-19 2021 – view presentation
CatalYm Presents at Bioequity Europe May 17-19 2021 – view presentation CatalYm-Bioequity-Corp-presentation-May-2021...
Read MoreCatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer
CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer Munich,...
Read MoreCatalYm Announces Key Management and Board Changes
CatalYm Announces Key Management and Board Changes Dr. Manfred Ruediger steps down...
Read MoreCatalYm Starts First-in-Human Phase I Clinical Trial with GDF-15 Neutralizing Antibody CTL-002 to Treat Patients with Checkpoint-Inhibitor Refractory Cancer
CatalYm Starts First-in-Human Phase I Clinical Trial with GDF-15 Neutralizing Antibody CTL-002...
Read MoreCatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for checkpoint-inhibitor refractory patients
CatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for...
Read More